Fatima Kalabi

Glaucoma is the subspecialty where “patient voice platforms” arguably deliver the greatest real-world impact because the clinical challenge is less about short-term decisional points and more about sustained behaviour over years: attending lifelong monitoring, instilling drops correctly, persisting with treatment despite limited symptoms, and navigating escalation to laser or surgery. Those are precisely the domains where organised patient communities, education hubs, and adherence support add value. This is particularly relevant in the context of persistent global vision impairment burden and health system emphasis on people-centred eye care, which explicitly positions community engagement and empowerment as part of delivery, not an optional adjunct (1,2).

1) Global Awareness and Collective Action: The Scaffolding That Normalises Participation

‘World Glaucoma Week,’ organised by the World Glaucoma Association, is the most visible annual patient-facing mobilisation in glaucoma, explicitly inviting patients, eye-care providers, health officials, and the public to organise and participate in awareness activities worldwide (3,4). Its strength in 2026 is not the sloganisation of risk, but the social permission it creates for practical actions – encouraging optic nerve checks, reinforcing family-history awareness, and prompting re-engagement of lapsed follow-up patients. Some participating organisations operationalise this directly as recall activity (e.g., calling back patients who missed reviews), illustrating how “campaigns” can translate into measurable pathway behaviour rather than generic awareness (5).

2) Condition Charities as Longitudinal Care Companions: Support, Navigation, And Trust

In the UK, ‘Glaucoma UK’ has matured into a comprehensive support platform spanning information, psychosocial support, and peer connection. Its helpline offers direct contact and explicitly uses translation services (Language Line), which matters for equitable access to advice and reassurance across language groups (6). The buddy scheme is a particularly high-yield patient voice model: it pairs patients who are worried about laser or surgery with someone who has first-hand experience for structured phone calls or chats, reducing anxiety and uncertainty around escalation decisions (7). Glaucoma UK also advertises support groups and an online forum as part of a broader “care and support” ecosystem, and the NHS condition page itself points patients to Glaucoma UK for support groups, forum, and buddy scheme – an external validation of its role as a trusted patient resource (8,9).

Outside the UK, a similar “national support hub” model is exemplified by ‘Glaucoma Australia,’ which positions itself as a community and education hub and provides a free support line for patients (10,11). From a service perspective, these national platforms are valuable because they provide continuity between visits: they can reinforce correct drop technique, help patients interpret symptoms and side effects, and support motivation to attend surveillance – needs that recur throughout the disease course.

3) Curated Education and Resource Centres: Reducing Noise and Preventing Misinformation Drift

One of the practical problems for glaucoma patients in 2026 is not lack of information, but excess information of variable quality. Several organisations now explicitly curate “safe” pathways through online resources:

• The ‘Glaucoma Research Foundation’ provides an organised list of patient resources and “web links” aimed at helping patients navigate the volume of glaucoma content online, alongside patient education materials intended for clinical distribution (12–14).
• ‘BrightFocus Foundation’ maintains glaucoma information and publishes updated resource lists for patients and caregivers, including signposting to accessible print/audio services and support options (15,16).
• ‘The Glaucoma Foundation’ hosts a patient resource centre focused on questions patients ask and how to engage with clinicians, linking to partner resources (17).

For ophthalmologists, the value proposition here is straightforward: these platforms can be used as “trusted extensions” of counselling, particularly for newly diagnosed patients, those considering procedural escalation, and those struggling with information overload.

4) Adherence And Persistence Supports: Where the Evidence Base Is Clearest

Glaucoma is where patient-facing platforms intersect most directly with robust intervention evidence because adherence is a dominant determinant of progression risk and service utilisation. A network meta-analysis of randomised trials indicates that tailored care improves glaucoma medication adherence compared with standard care and that multifaceted approaches may confer additional benefit (18). Complementing this, a systematic review using behavioural theory (Theoretical Domains Framework) identifies modifiable barriers and enablers – skills/technique, memory/attention, beliefs about consequences, environmental context – explaining why purely informational interventions often underperform when they do not address the patient’s specific determinant profile (19).

At the pragmatic end, the ‘Automated Dosing Reminder Study’ demonstrated that automated telecommunication reminders linked to a personal health record improved adherence with once-daily glaucoma medication dosing (20). The wider implication for “platforms” in 2026 is not that any single reminder tool is universally effective, but that scalable, low-friction reminder and support mechanisms can produce measurable benefit when deployed for the right patients – especially those identified as non-adherent.

References

1. Steinmetz JD, Bourne RRA, Briant PS, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020. Lancet Glob Health. 2021;9(2):e144–e160.
2. World Health Organization. World report on vision. Geneva: WHO; 2019.
3. World Glaucoma Week. World Glaucoma Week campaign website. Accessed 2026 Jan 20. (worldglaucomaweek.org)
4. World Glaucoma Association. World Glaucoma Week 2026 call for activities. Accessed 2026 Jan 20. (wga.one)
5. World Glaucoma Week. Example campaign activity describing recall/engagement for follow-up compliance. Accessed 2026 Jan 20. (worldglaucomaweek.org)
6. Glaucoma UK. Glaucoma helpline (including translation support). Accessed 2026 Jan 20. (Glaucoma UK)
7. Glaucoma UK. Buddy scheme. Accessed 2026 Jan 20. (Glaucoma UK)
8. Glaucoma UK. Care & support overview (helpline, forum, buddy scheme). Accessed 2026 Jan 20. (Glaucoma UK)
9. NHS. Glaucoma—support links to Glaucoma UK (forum, support groups, buddy scheme). Accessed 2026 Jan 20. (nhs.uk)
10. Glaucoma Australia. Your Support Network. Accessed 2026 Jan 20. (10) (glaucoma.org.au)
11. Glaucoma Australia. Contact and free patient support line. Accessed 2026 Jan 20. (glaucoma.org.au)
12. Glaucoma Research Foundation. Glaucoma patient resources (organised links). Accessed 2026 Jan 20. (Glaucoma Research Foundation)
13. Glaucoma Research Foundation. Online glaucoma resources (regularly updated list). Accessed 2026 Jan 20. (Glaucoma Research Foundation)
14. Glaucoma Research Foundation. Patient education materials for practices. Accessed 2026 Jan 20. (Glaucoma Research Foundation)
15. BrightFocus Foundation. Glaucoma information hub. Accessed 2026 Jan 20. (BrightFocus Foundation)
16. BrightFocus Foundation. Helpful resources for glaucoma care (patients and caregivers). 2025 Sep 30. Accessed 2026 Jan 20. (BrightFocus Foundation)
17. The Glaucoma Foundation. Glaucoma Patient Resource Center. Accessed 2026 Jan 20. (The Glaucoma Foundation)
18. Ha A, Jang M, Shim SR, et al. Interventions for glaucoma medication adherence improvement: a network meta-analysis of randomized controlled trials. Ophthalmology. 2022;129(11). doi:10.1016/j.ophtha.2022.06.025. (PubMed)
19. Bott D, Subramanian A, Edgar D, Lawrenson JG, Campbell P. Barriers and enablers to medication adherence in glaucoma: a systematic review of modifiable factors using the Theoretical Domains Framework. Ophthalmic Physiol Opt. 2024. doi:10.1111/opo.13245. (PubMed)
20. Boland MV, Chang DS, Frazier T, et al. Automated telecommunication-based reminders and adherence with once-daily glaucoma medication dosing: the Automated Dosing Reminder Study. JAMA Ophthalmol. 2014;132(7):845–850. doi:10.1001/jamaophthalmol.2014.857. (PubMed)